A Brief Primer and Updates on Native American Youth Substance Use Disorder (SUD)

Steven Sust, MD
Clinical Assistant Professor
June 22, 2023
Disclosure Statement

• Faculty Disclosure Statement: As a jointly accredited provider of continuing education, the IHS Clinical Support Center must ensure balance, independence, objectivity, and scientific rigor in its educational activities. Course directors/coordinators, planning committee members, faculty, reviewers and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty will also disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. All those who are in a position to control the content of this educational activity have completed the disclosure process and have indicated that they do not have any relevant financial relationships or affiliations with any manufacturers or commercial products to disclose.

• There is no commercial interest support for this educational activity.

Disclaimer

The views expressed in this presentation are those of the speaker and do not necessarily represent the views, policies, and positions of the Indian Health Service (IHS), or the U.S. Department of Health and Human Services (HHS).
Introducing the Presenter

Steven Sust is the middle child of 3 boys born to Hong Kong immigrant parents who raised them in downtown Philadelphia. He received a bachelor’s degree in psychology from GWU, medical degree from UVA, and postgraduate training at UPenn and Stanford. His work experiences range broadly from state psychiatric hospitals, county specialty MH clinics and emergency rooms to school mental health and schizophrenia research at NIMH. Current interests include primary care behavioral health integration, cultural psychiatry, school mental health, and working with underserved populations.
Personal Disclosures

• I am a cisgender male of Cuban influenced Chinese descent
• I have no formally diagnosed family history of mental illness
• I have sought out and received my own mental health care
• I have both knowingly and unknowingly contributed to bias and most “isms,” and will try to improve upon these areas of growth
Learning objectives

• Recognize psychiatric comorbidities that could pre-date initial diagnosis of SUD
• List two to three methods of screening for youth SUD
• Acquire new knowledge regarding cultural and psychosocial stressors affecting psychiatric and SUD that requires close collaboration between clinicians, schools, parents, and children
POP QUIZ!

True or false:

It is **not** important for patients to disclose quantity and frequency of marijuana use to their surgical team(s) before they operate on patients.
Marijuana Affecting Anesthesia

Effects of Cannabis Use on Sedation Requirements for Endoscopic Procedures
Mark A. Twardowski, DO; Margaret M. Link, MSN, RN, CRNI; Nicole M. Twardowski, BS

Context: Cannabis (or marijuana) became legal for recreational use in Colorado in 2012, and this legislation change has created both challenges and opportunities in medicine. More patients are using cannabis, and more patients are now willing to admit cannabis use than in the past, which increases the likelihood that they will be forthcoming about use during medical questioning. Cannabis use may have implications during medical care, including procedural sedation.

Objective: To determine whether regular cannabis use had any effect on the dose of medication needed for sedation during endoscopic procedures.

Methods: A total of 250 medical records were reviewed from 1 endoscopy center and 1 endoscopist to minimize the variability in sedation technique for the study purposes. The cohort was reviewed with regard to age and gender to determine whether differences were present among different groups as to the relative amount of sedation medication required in cannabis users vs nonusers.

Results: Medical records from 250 patients were reviewed, and researchers found that compared with people who did not regularly use cannabis, people who regularly used cannabis required an amount of sedation for endoscopic procedures that was significantly higher ($P<.05$).

Conclusion: Determining cannabis use before procedural sedation can be an important tool for planning patient care and assessing both medication needs and possible risks related to increased dosage requirements during endoscopic procedures.


Keywords: cannabis, endoscopy, marijuana, sedation
Context and Humility

“To be fully culturally competent, practitioners should understand the meaning of the NA/AI experience by understanding that, collectively, Native people have been wounded through the processes of genocide, removal, assimilation, acculturation, and loss of culture.”
Mechanism by which Adverse Childhood Experiences Influence Health and Well-being Throughout the Lifespan
Imperfect Epidemiology Data

Original Investigation | Substance Use and Addiction

Substance Use Among American Indian Youths on Reservations Compared With a National Sample of U.S. Adolescents

Randal C. Swaim, PhD; Linda R. Stanley, PhD

Abstract

IMPORANCE American Indian adolescents attending schools on or near reservations are historically at high risk for substance use.

OBJECTIVE To compare rates of substance use among reservation-based American Indian adolescents vs rates among national U.S. youths.

DESIGN, SETTING, AND PARTICIPANTS Population-based survey study of 8th-, 10th-, and 12th-grade students attending participating schools on or near reservations, stratified by region, during the 2016-2017 school year. Substance use rates were compared with those of a national sample of comparably aged students from the Monitoring the Future study.

MAIN OUTCOMES AND MEASURES Lifetime and last-30-day self-reported use of alcohol, marijuana, and other drugs, using relative risk (RR) ratios with 95% confidence intervals to compare American Indian student rates with Monitoring the Future student rates.

RESULTS Participants included 570 students in eighth grade (49.6% girls; mean age, 13.5 years), 582 in 10th grade (50.0% girls; mean age, 15.4 years), and 508 in 12th grade (53.5% girls; mean age, 17.4 years). American Indian students reported substantially higher lifetime and last-30-day substance use rates compared with the Monitoring the Future students, with greatest disparity at eighth grade: last-30-day substance use RRs for grade 8 were 2.1 (95% CI, 1.4-3.0) for alcohol, 4.2 (95% CI, 3.1-5.8) for marijuana, and 2.4 (95% CI, 1.7-3.3) for other illicit drugs. Compared with 2009 to 2012 data, the RRs between American Indian and Monitoring the Future students for lifetime alcohol and marijuana use did not change substantially from the 2016-2017 school year (alcohol: RR, 1.5 [95% CI, 1.4-1.6] vs RR, 1.3 [95% CI, 1.2-1.4], respectively; marijuana: RR, 2.0 [95% CI, 1.8-2.1] vs RR, 2.1 [95% CI, 1.9-2.3], respectively), but increased substantially for other drugs (RR, 1.8 [95% CI, 1.7-1.9] vs RR, 3.0 [95% CI, 2.9-3.2], respectively).

CONCLUSIONS AND RELEVANCE Reservation-based American Indian students are at high risk for substance use compared with US youths in general, making prevention efforts critical. Cultural and value-based characteristics unique to American Indian populations may provide beneficial targets for prevention, but there is limited evidence on how cultural factors work to prevent risky behaviors. Without increased attention to these disparities, the costs to American Indian youths and their communities will remain high.
## Screening for SUD in Youth

### TABLE 2

**Key Characteristics of Substance Use Screening Tools**

<table>
<thead>
<tr>
<th>Screening tool</th>
<th>Patients</th>
<th>Time to administer</th>
<th>Optimal cut-point associated with problem use</th>
<th>Sensitivity (95% CI)</th>
<th>Specificity (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol Use Disorders Identification Test (AUDIT)³⁷</td>
<td>13 to 19 years of age; college students; emergency department patients</td>
<td>2 minutes</td>
<td>2</td>
<td>0.88 (0.83 to 0.93)</td>
<td>0.81 (0.77 to 0.85)</td>
</tr>
<tr>
<td>CAGE Questionnaire*³⁷</td>
<td>Adults (not recommended for use with adolescents)</td>
<td>Not applicable (not recommended for use with adolescents)</td>
<td>1</td>
<td>0.37 (0.29 to 0.44)</td>
<td>0.96 (0.94 to 0.98)</td>
</tr>
<tr>
<td>CRAFFT Questionnaire†³⁷</td>
<td>14 to 18 years of age</td>
<td>74 seconds via paper; 49 seconds via computer</td>
<td>1</td>
<td>0.92 (0.88 to 0.96)</td>
<td>0.64 (0.59 to 0.69)</td>
</tr>
<tr>
<td>National Institute on Alcohol Abuse and Alcoholism (NIAAA) Screening Guide³⁸</td>
<td>Offers age-specific screening questions (9 to 11, 11 to 14, and 14 to 18 years of age)</td>
<td>Not documented; only two questions in length</td>
<td>Varies by age</td>
<td>0.87 (0.76 to 0.94)</td>
<td>0.84 (0.82 to 0.86)</td>
</tr>
<tr>
<td>Problem Oriented Screening Instrument for Teenagers (POSIT)³⁷</td>
<td>12 to 19 years of age</td>
<td>20 to 30 minutes</td>
<td>1</td>
<td>0.84 (0.79 to 0.90)</td>
<td>0.89 (0.86 to 0.92)</td>
</tr>
</tbody>
</table>

Validity of the CRAFFT in American-Indian and Alaska-Native Adolescents: Screening for Drug and Alcohol Risk*

LILLIAN HUANG CUMMINS, PH.D.,† KAREN K. CHAN, M.S., KELLY M. BURNS, B.A., ARTHUR W. BLUME, PH.D.,† MARY LARIMER, PH.D., AND G. ALAN MARLATT, PH.D.

Department of Psychology, University of Washington, Seattle, Washington

ABSTRACT. Objective: Native-American adolescents are reported to be at high risk for drug and alcohol use and related negative consequences. A brief screening instrument that is culturally and developmentally appropriate can aid clinicians who work with Native youth in determining whether more extensive assessment of substance use is necessary. The CRAFFT has been shown to be a valid and reliable screen among general adolescent outpatient clinic samples. Method: Data were collected as part of the Journeys of the Circle project, a collaborative effort between the Seattle Indian Health Board (SIHB) and the University of Washington’s Addictive Behaviors Research Center. Psychometric properties of the CRAFFT were examined in 70 American-Indian and Alaska-Native youths ages 13 to 19 recruited from public schools and SIHB’s outpatient clinics. Results: The CRAFFT demonstrated good internal consistency (α = 0.81). A score of 2 or higher on the CRAFFT was found to be optimal for capturing youths with high alcohol-related problems (sensitivity, 0.95; specificity, 0.86), frequent alcohol use (sensitivity, 1.00; specificity, 0.72) and frequent marijuana use (sensitivity, 1.00; specificity, 0.75). A cut-point of 3 was appropriate for identifying adolescents with frequent other drug use (sensitivity, 0.86; specificity, 0.76). Conclusions: The CRAFFT may be a valid instrument for identifying Native youths at risk for alcohol and other drug problems. This brief screen can be effective in helping providers determine the need for further assessment and treatment or prevention services for Native-American adolescents. (J. Stud. Alcohol 64: 727-732, 2003)
The CRAFFT 2.1+N Interview
To be verbally administered by the clinician

Begin: “I'm going to ask you a few questions that I ask all my patients. Please be honest. I will keep your answers confidential.”

**Part A**
During the PAST 12 MONTHS, on how many days did you:

1. Drink more than a few sips of beer, wine, or any drink containing **alcohol**? Say “0” if none.

2. Use any **marijuana** (cannabis, weed, oil, wax, or hash by smoking, vaping, dabbing, or in edibles) or **“synthetic marijuana”** (like “K2,” “Spice”)? Say “0” if none.

3. Use **anything else to get high** (like other illegal drugs, pills, prescription or over-the-counter medications, and things that you sniff, huff, vape, or inject)? Say “0” if none.

4. Use a **vaping device** containing **nicotine and/or flavors**, or use any **tobacco products**? Say “0” if none.
   *Such as e-cigs, mods, pod devices like JUUL, disposable vapes like Puff Bar, vape pens, or e-hookahs. †Cigarettes, cigars, cigarillos, hookahs, chewing tobacco, snuff, snus, dissolvables, or nicotine pouches.*
Alcohol Use Disorders Identification Test-Concise (AUDIT-C)

General Instructions
The Alcohol Use Disorders Identification Test-Concise (AUDIT-C) is a brief alcohol screening instrument. Please give a response for each question.

Segment: __ __

Visit Number: __ __

1. How often do you have a drink containing alcohol?
   □ Never
   □ Monthly or less
   □ 2-4 times a month
   □ 2-3 times a week
   □ 4 or more times a week

2. How many standard drinks containing alcohol do you have on a typical day?
   □ 1 or 2
   □ 3 to 4
   □ 5 to 6
   □ 7 to 9
   □ 10 or more

3. How often do you have six or more drinks on one occasion?
   □ Daily or almost daily
   □ Weekly
   □ Monthly
   □ Less than monthly
   □ Never
## Imperfect Epidemiology Data (Cont’d)

### Table 1. Lifetime Prevalence of Alcohol and Drug Use Comparing Reservation-Based American Indian Students (2016-2017) With MTF Students (2016)

<table>
<thead>
<tr>
<th>Type of Substance Use</th>
<th>Grade 8 American Indian, % (95% CI)</th>
<th>MTF, %a</th>
<th>RR (95% CI)</th>
<th>Grade 10 American Indian, % (95% CI)</th>
<th>MTF, %a</th>
<th>RR (95% CI)</th>
<th>Grade 12 American Indian, % (95% CI)</th>
<th>MTF, %a</th>
<th>RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol</td>
<td>39.7 (31.4-48.6)</td>
<td>22.8</td>
<td>1.7 (1.4-2.2)b</td>
<td>52.9 (46.5-59.2)</td>
<td>43.4</td>
<td>1.2 (1.1-1.4)b</td>
<td>72.5 (66.0-78.1)</td>
<td>61.2</td>
<td>1.2 (1.1-1.3)b</td>
</tr>
<tr>
<td>Been drunk</td>
<td>22.9 (17.3-29.7)</td>
<td>8.6</td>
<td>2.7 (2.0-3.5)b</td>
<td>39.2 (31.6-47.4)</td>
<td>26.0</td>
<td>1.5 (1.2-1.9)b</td>
<td>56.5 (49.2-63.5)</td>
<td>46.3</td>
<td>1.2 (1.0-1.4)b</td>
</tr>
<tr>
<td>Marijuana</td>
<td>43.7 (35.1-52.7)</td>
<td>12.8</td>
<td>3.4 (2.8-4.2)b</td>
<td>55.6 (46.7-64.2)</td>
<td>29.7</td>
<td>1.9 (1.6-2.2)b</td>
<td>66.4 (57.3-74.5)</td>
<td>44.5</td>
<td>1.5 (1.3-1.7)b</td>
</tr>
<tr>
<td>Any illicit drug, not marijuanac</td>
<td>16.2 (12.7-20.5)</td>
<td>8.9</td>
<td>1.8 (1.5-2.3)b</td>
<td>19.1 (12.8-27.6)</td>
<td>14.0</td>
<td>1.4 (0.9-2.0)</td>
<td>24.4 (18.8-31.0)</td>
<td>20.7</td>
<td>1.2 (0.9-1.5)</td>
</tr>
<tr>
<td>Inhalants</td>
<td>13.2 (9.7-17.7)</td>
<td>7.7</td>
<td>1.7 (1.3-2.3)b</td>
<td>10.7 (8.6-13.1)</td>
<td>6.6</td>
<td>1.6 (1.3-2.1)b</td>
<td>10.8 (8.0-14.3)</td>
<td>5.0</td>
<td>2.2 (1.3-3.5)b</td>
</tr>
<tr>
<td>Tranquilizers</td>
<td>3.6 (2.2-5.7)</td>
<td>3.0</td>
<td>1.2 (0.8-2.0)</td>
<td>6.2 (3.6-10.7)</td>
<td>6.1</td>
<td>1.0 (0.6-1.7)</td>
<td>5.0 (3.5-7.1)</td>
<td>7.6</td>
<td>0.7 (0.5-0.9)b</td>
</tr>
<tr>
<td>Narcotics other than heroin</td>
<td>3.0 (2.0-4.5)</td>
<td>NA</td>
<td>NA</td>
<td>8.1 (5.2-12.3)</td>
<td>NA</td>
<td>NA</td>
<td>10.9 (7.6-15.4)</td>
<td>7.8</td>
<td>1.4 (0.9-2.0)</td>
</tr>
<tr>
<td>Amphetamines</td>
<td>4.0 (2.3-6.8)</td>
<td>5.7</td>
<td>0.7 (0.5-1.2)</td>
<td>5.8 (3.5-9.4)</td>
<td>8.8</td>
<td>0.7 (0.4-1.1)</td>
<td>10.0 (5.9-16.4)</td>
<td>10.0</td>
<td>1.0 (0.7-1.5)</td>
</tr>
<tr>
<td>Cocaine</td>
<td>4.3 (2.8-6.5)</td>
<td>1.1</td>
<td>3.9 (2.3-6.5)b</td>
<td>6.4 (3.6-11.0)</td>
<td>1.9</td>
<td>3.4 (1.8-6.0)b</td>
<td>11.8 (8.3-16.4)</td>
<td>3.3</td>
<td>3.6 (2.3-5.4)b</td>
</tr>
<tr>
<td>Crack</td>
<td>3.0 (1.7-5.2)</td>
<td>0.9</td>
<td>3.3 (1.8-5.7)b</td>
<td>3.8 (2.3-6.2)</td>
<td>0.8</td>
<td>4.8 (2.8-8.2)b</td>
<td>5.6 (3.4-9.3)</td>
<td>1.4</td>
<td>4.0 (2.2-6.9)b</td>
</tr>
<tr>
<td>LSD</td>
<td>3.9 (2.6-5.9)</td>
<td>1.2</td>
<td>3.3 (2.1-5.1)b</td>
<td>6.1 (3.6-10.3)</td>
<td>3.2</td>
<td>1.9 (1.2-3.3)b</td>
<td>9.8 (6.3-14.9)</td>
<td>4.9</td>
<td>2.0 (1.2-3.2)b</td>
</tr>
<tr>
<td>Hallucinogens other than LSD</td>
<td>8.1 (5.6-11.6)</td>
<td>1.9</td>
<td>4.3 (2.8-6.4)</td>
<td>9.9 (7.3-13.4)</td>
<td>3.1</td>
<td>3.2 (2.3-4.4)</td>
<td>12.3 (8.6-17.4)</td>
<td>4.7</td>
<td>2.8 (1.9-4.1)b</td>
</tr>
<tr>
<td>Heroin</td>
<td>2.8 (1.8-4.3)</td>
<td>0.5</td>
<td>5.6 (3.3-9.8)b</td>
<td>2.4 (1.4-3.9)</td>
<td>0.6</td>
<td>4.0 (2.3-7.4)b</td>
<td>3.2 (2.2-4.6)</td>
<td>0.7</td>
<td>4.6 (2.9-7.3)b</td>
</tr>
<tr>
<td>Crystal methd</td>
<td>2.6 (1.4-4.8)</td>
<td>0.6</td>
<td>4.3 (2.2-7.9)b</td>
<td>5.3 (4.0-7.0)</td>
<td>0.7</td>
<td>7.6 (5.1-10.8)b</td>
<td>8.0 (4.2-14.7)</td>
<td>1.4</td>
<td>5.7 (3.0-12.6)b</td>
</tr>
<tr>
<td>Cigarettes</td>
<td>29.7 (22.4-38.1)</td>
<td>9.8</td>
<td>3.0 (2.3-4.0)b</td>
<td>42.0 (36.2-47.9)</td>
<td>17.5</td>
<td>2.4 (2.0-2.8)b</td>
<td>49.7 (44.2-55.1)</td>
<td>28.3</td>
<td>1.8 (1.6-2.01)b</td>
</tr>
</tbody>
</table>

Abbreviations: LSD, lysergic acid diethylamide; MTF, Monitoring the Future; NA, not available; RR, relative risk.

a Confidence intervals for MTF data can be found in Miech et al.19 Tables 4-1a through d.

b P < .05.

c Use of any illicit drug includes any use of LSD, other hallucinogens, crack, cocaine other than crack, heroin, any use of narcotics other than heroin (grade 12 only), amphetamines, or tranquilizers not under a physician’s orders.

d Numbers for MTF grades 8 and 10 are for methamphetamine (including crystal meth).
### Table 3: DSM-5 Diagnostic Criteria for Diagnosing and Classifying Substance Use Disorders [a,b,c]

<table>
<thead>
<tr>
<th>Criteria Type</th>
<th>Descriptions</th>
</tr>
</thead>
</table>
| Impaired control over substance use (DSM-5 criteria 1 to 4) | • Consuming the substance in larger amounts and for a longer amount of time than intended.  
• Persistent desire to cut down or regulate use. The individual may have unsuccessfully attempted to stop in the past.  
• Spending a great deal of time obtaining, using, or recovering from the effects of substance use.  
• Experiencing craving, a pressing desire to use the substance. |
| Social impairment (DSM-5 criteria 5 to 7)           | • Substance use impairs ability to fulfill major obligations at work, school, or home.  
• Continued use of the substance despite it causing significant social or interpersonal problems.  
• Reduction or discontinuation of recreational, social, or occupational activities because of substance use. |
| Risky use (DSM-5 criteria 8 and 9)                  | • Recurrent substance use in physically unsafe environments.  
• Persistent substance use despite knowledge that it may cause or exacerbate physical or psychological problems. |
| Pharmacologic (DSM-5 criteria 10 and 11)            | • **Tolerance**: Individual requires increasingly higher doses of the substance to achieve the desired effect, or the usual dose has a reduced effect; individuals may build tolerance to specific symptoms at different rates.  
• **Withdrawal**: A collection of signs and symptoms that occurs when blood and tissue levels of the substance decrease. Individuals are likely to seek the substance to relieve symptoms. No documented withdrawal symptoms from hallucinogens, PCP, or inhalants.  
• **Note**: Individuals can have an SUD with prescription medications, so tolerance and withdrawal (criteria 10 and 11) in the context of appropriate medical treatment do not count as criteria for an SUD. |

**Abbreviations:** DSM-5, Diagnostic and Statistical Manual of Mental Disorders–5; PCP, phencyclidine; SUD, substance use disorder.

**Notes:**

- Adapted from [APA 2013].
- SUDs are classified as mild, moderate, or severe based on how many of the 11 criteria are fulfilled: mild, any 2 or 3 criteria; moderate, any 4 or 5 criteria; severe, any 6 or more criteria.
- Please consult the DSM-5 for substance-specific diagnostic information.
Neurobiology of Addiction

Transcription factors:
D1: ΔFosB, CREB
D2: ΔFosB (opioids only), CREB
Chromatin and DNA modifiers:
HATs, HDACs, HMTs, DNMTs, etc.

Target gene products:
ion channels, receptors, intracellular signalling and cytoskeletal proteins

Long-lasting adaptive changes in neuronal function
Early Death

Disease, Disability, & Social Problems

Adoption of Health Risk Behavior

Social, Emotional, & Cognitive Impairment

Disrupted Neurodevelopment

Adverse Childhood Experiences

Social Conditions / Local Context

Generational Embodiment / Historical Trauma

Mechanism by which Adverse Childhood Experiences Influence Health and Well-being Throughout the Lifespan

Death

Conception

CALIFORNIA AREA INDIAN HEALTH SERVICE
Project ECHO®

Link to CDC ACES page
Empathy and Support

**Steps to Mirroring**

1. **Listen carefully and attentively**
2. **Imagine their perspective and feelings**
3. **Stay out of judgment (avoid blockers)**
4. **Paraphrase their feelings and problems**

Practice mirroring using sentence stems and avoid empathy blockers - well intentioned statements that may communicate judgment by shifting the attention away from the person who needs to be heard.

**Mirroring Sentence Stems**

- It sounds like you are feeling...
- I'm hearing you say that you...
- I wonder if you feel...
- It seems like you are needing...

**Common Empathy Blockers**

- **Silverlining It**
  - Reassuring, cheering up, downplaying, trying to make them feel better or differently
- **Fixer Upper**
  - Offering your solutions, advice, beliefs, or opinions
- **Interrogating**
  - Probing, analyzing, evaluating
Motivational Interviewing

- **Pre-Contemplation**: The person likely does not see a problem with their behavior and has no thoughts about changing it.
- **Contemplation**: The person is aware there is a problem but has not yet decided to make changes.
- **Action**: The person is actively taking steps towards change.
- **Preparation**: The person is actively making plans to change their behavior.
- **Maintenance**: The person is sustaining their behavior change.
- **Relapse**: The person falls back into old behaviors, at any point in the stages.

Use Mi to:
- **Pre-Contemplation**: Raise awareness.
- **Contemplation**: Resolve ambivalence.
- **Action**: Help implement changes.
- **Preparation**: Plan strategies.
- **Relapse**: Develop & continue new skills.

The person learns from each relapse.

Link to motivational interviewing resources
Link to article containing image
Summary

1. Strong possibility of both diagnoses for both psychiatric and substance use disorder
2. Work with cultural practitioner(s) to review all screeners before implementation
3. People who struggle with SUD deserve equal parts of compassion and empathy as well
References & Resources

• Please see direct URL links embedded in slides for presentation references

• Additional Resource
  – Native American Motivational Interviewing: Weaving Native American and Western Practices
Presenter Contact Information

Steven Sust, MD
susts@stanford.edu